Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape
Snapshot: 2026-09-04

Chongqing Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 20 active clinical trials for multiple myeloma hosted across 8 tertiary medical centers in Chongqing (including Chongqing University Cancer Hospital, Chongqing University Cancer Hospital (Chongqing Cancer Hospital), The First Affiliated Hospital of Chongqing Medical University, etc.).

Active Trials
20
Hospitals
8
Therapies
CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (8)

Chongqing University Cancer HospitalChongqing University Cancer Hospital (Chongqing Cancer Hospital)The First Affiliated Hospital of Chongqing Medical UniversityThe Second Affiliated Hospital of Army Medical University重庆医科大学附属第二医院Chongqing University Three Gorges HospitalXinqiao Hospital, Army Medical University (The Second Affiliated Hospital of Army Medical University)Xinqiao Hospital, Army Medical University

Active Studies in Chongqing (20)

Population synthesized by CMDN

Showing 0 published English records of 20 registry trials.

All 20 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.